Artificial, a provider of cloud-based solutions for streamlining life science laboratories’ operations, has shared the results of a proof-of-concept designed to showcase the integration of its laboratory orchestration platform with Nvidia’s BioNeMo artificial intelligence (AI) platform for chemistry and biology.
Artificial’s platform integrates instruments, devices, people, and data systems in the laboratory. The platform features an open application programming interface library and adapter modules and incorporates BioNeMo’s AI and machine learning modeling capabilities into its workflows. BioNeMo is a collection of ready-made tools for designing and training biomolecular AI models for drug discovery, protein engineering, and virtual screening processes.
The proof-of-concept was designed to demonstrate the power of pairing AI with lab orchestration to automate molecular screening. Using both solutions, Artificial automated a workflow for screening candidate compounds for the SARS-CoV-2 main protease which is critical for viral replication and a target for COVID-19 therapies. The results “successfully demonstrated how AI-driven methodologies can accelerate virtual screening and drug discovery processes,” the company stated.
While highlighting the benefits of the integration, Artificial’s CEO David Fuller noted that “to accelerate the development of gene therapies and life-saving drugs, or rapid pandemic response, the industry is increasingly recognizing the importance of adopting the latest breakthroughs in AI and machine learning—it is where the market is heading.”
The company also announced that it has received ISO 27001 and SOC 2 accreditations, which “reflect our dedication to our customers’ security and compliance needs and give them confidence in our solutions as they go on this journey,” he added. ISO 27001, the international standard for information security management, validates Artificial’s framework for protecting data and minimizing security risks. The SOC 2 accreditation recognizes the company’s operational transparency and commitment to safeguarding sensitive information.
Artificial will showcase its platform during the 2025 Society of Laboratory Automation and Screening Conference which is taking place in San Diego, CA.
The partnership with Artificial is just one of several involving the use of Nvidia’s artificial intelligence capabilities. Recently, Nvidia announced a partnership with Mayo Clinic focused on applying AI to digital pathology. The company also has an agreement with Illumina to pair AI and genomics technologies for use in drug discovery, clinical research, and health applications.
